Ardelyx vs Arcutis Biotherapeutics
Ardelyx and Arcutis Biotherapeutics are similar in size: $407m and $376m of revenue in their latest fiscal years. Arcutis Biotherapeutics grew faster (91.3% against 22.1%). Arcutis Biotherapeutics kept more of each dollar of sales as profit: a net margin of -4.3% against -15.1%. Arcutis Biotherapeutics carries less debt relative to equity (57.5% against 121.5%).
| Latest fiscal year | ArdelyxARDX, 2025 | Arcutis BiotherapeuticsARQT, 2025 |
|---|---|---|
| Revenue | $407m | $376m |
| Revenue growth | 22.1% | 91.3% |
| Net income | −$61.6m | −$16.1m |
| Operating margin | -10.1% | -3.3% |
| Net margin | -15.1% | -4.3% |
| Return on equity | -36.2% | -9.3% |
| Free cash flow | −$44.0m | −$6.3m |
| Cash | $68.0m | $42.9m |
| Total debt | $203m | $109m |
| Debt to equity | 121.5% | 57.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 489 | 354 |
| Market value | $755m | $4.02bn |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 1 buys, 77 sales | 0 buys, 77 sales |